Business Context and Reporting Period
Company: Zai Lab Limited (Zai Lab)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Nine months ended September 30, 2019
Filing Date: January 21, 2020
Zai Lab is a biopharmaceutical company focused on discovering, licensing, developing, and commercializing proprietary therapeutics for oncology, infectious, and autoimmune diseases, primarily in the China market. The company operates through subsidiaries in Hong Kong, China, Australia, and the U.S.
Key Financial Metrics
| Metric | Nine Months Ended Sept 30, 2019 | Nine Months Ended Sept 30, 2018 |
|---|---|---|
| Revenue | $8,339,732 | $0 |
| Cost of Sales | $2,173,767 | $0 |
| Gross Profit | $6,165,965 | $0 |
| Research & Development (R&D) Expenses | $110,125,563 | $64,625,210 |
| Selling, General & Administrative (SG&A) Expenses | $47,186,808 | $10,599,246 |
| Net Loss | $(148,640,670) | $(75,717,598) |
| Loss Per Share (Basic & Diluted) | $(2.35) | $(1.49) |
| Cash, Cash Equivalents & Restricted Cash | $69,217,759 | $104,957,732 |
| Short-term Investments | $251,600,000 | $200,350,000 |
| Short-term Borrowings | $6,362,312 | $3,642,616 |
| Total Shareholders' Equity | $337,112,988 | $251,081,713 |
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from zero revenue to $8.3 million, driven by the commercial launch of Niraparib (ZEJULA) and Optune in the Hong Kong market.
- Expense Growth: Operating expenses increased significantly. R&D expenses rose 70% to $110.1 million due to two new licensing projects and ongoing clinical trials. SG&A expenses increased 345% to $47.2 million, attributed to commercial launches in Hong Kong and preparations for Mainland China.
- Net Loss Expansion: Net loss more than doubled to $148.6 million, reflecting the heavy investment in R&D and commercialization infrastructure.
- Capital Structure: The company raised significant capital through a follow-on public offering, resulting in a net increase in cash and short-term investments despite high operating cash burn. Total assets grew from $302 million to $392 million.
- Debt: Short-term borrowings increased from $3.6 million to $6.4 million, primarily due to new facility agreements with local commercial banks in China.
Outlook, Risks, and Contingencies
- Regulatory Milestone: On December 27, 2019, the China National Medical Products Administration (NMPA) approved the New Drug Application for ZEJULA (niraparib). This triggered a milestone payment obligation to partner Tesaro.
- Licensing Obligations: The company has entered into multiple exclusive license agreements (e.g., with Tesaro, Novocure, MacroGenics, Deciphera, Incyte) involving significant upfront payments and contingent future milestone payments and royalties based on development, regulatory, and sales achievements.
- Share-Based Compensation: As of September 30, 2019, there was $48.2 million of unrecognized compensation expense related to unvested share options and $14.8 million related to non-vested restricted shares, expected to be recognized over the next 2.3 years.
- Foreign Currency Risk: A portion of cash and cash equivalents is denominated in Renminbi (RMB), which is subject to foreign exchange controls and valuation fluctuations.
- Liquidity: While the company holds substantial cash and short-term investments ($320.8 million combined), it continues to operate at a significant loss and relies on capital markets or financing for future operations.
Investor Verification Checklist
- Verify the commercial performance and sales trajectory of Niraparib and Optune in Hong Kong and the timeline for Mainland China launch.
- Confirm the specific amounts and timing of milestone payments due to partners (Tesaro, Novocure, etc.) triggered by the NMPA approval of ZEJULA.
- Assess the burn rate relative to the current cash and short-term investment balance to determine runway without further capital raises.
- Review the status of clinical trials for the pipeline assets (e.g., FPA144, ETX2514, Margetuximab) to gauge future R&D expense requirements.
- Monitor the impact of foreign exchange rates on the company's financial statements, given the mix of USD, RMB, and HKD assets.